Online discussion of cannabis and cancer ranges between two extremes: claims that cannabis cures cancer, and suggestions that cannabinoids have no medical role in oncology. Treating the tumour must be distinguished from relieving symptoms caused by cancer or its treatment.
Cannabinoids have been studied for treatment side effects and for laboratory effects on cancer cells. Certain cannabinoid medicines have clinical evidence for symptoms such as chemotherapy-related nausea. However, the CDC overview and US National Cancer Institute summary do not establish cannabis or cannabis oil as a human cancer cure. Unproven products must not replace evidence-based treatment.
Three different questions need separating:
- can cannabis or cannabinoids relieve symptoms of cancer or its treatment;
- do cannabinoids affect cancer cells in laboratory conditions;
- is cannabis itself an established cancer treatment?
These are not equivalent.
Does cannabis cure cancer?
Current clinical evidence does not establish that cannabis cures cancer.
THC, CBD and other cannabinoids have shown interesting effects in laboratory and animal experiments.
Researchers have investigated possible effects on:
- cancer-cell proliferation;
- programmed cell death;
- inflammation;
- tumour blood supply;
- cell-signalling pathways.
These findings justify further research.
An effect in a dish or mouse does not establish that a substance treats a human tumour.
A medicine must reach the right tissue at an effective concentration, affect the tumour, be tolerable and improve meaningful outcomes such as progression or survival. Cannabis does not currently have sufficient evidence for this claim.
Why are laboratory studies insufficient?
Many substances can damage cancer cells in a laboratory without becoming effective, safe human cancer medicines.
Reasons include:
- the required dose being too toxic;
- insufficient delivery to the tumour;
- a tumour behaving differently in the body than in cell culture;
- rapid breakdown of the compound;
- side effects limiting the dose;
- a laboratory effect failing to improve survival.
Clinical trials are therefore essential.
What about the 2025 analysis of over 10,000 papers?
On 15 April 2025, Frontiers in Oncology published a large literature analysis examining 10,641 papers about cannabis, possible medical uses and cancer. Its 39,767 text-derived data points were not an equivalent number of patients or clinical outcomes.

The paper attracted attention because its authors found broadly supportive literature on potential medical benefits, including symptom relief and further investigation of possible antitumour effects.
This was not a pooling of patient outcomes from 10,000 controlled cancer trials into one treatment-effect estimate.
Much of the method automatically classified supportive, unsupportive and unclear statements in scientific texts. That can describe patterns in the literature, but does not itself demonstrate a treatment’s effectiveness.
The authors acknowledged that sentiment analysis cannot measure individual treatment outcomes and can misclassify scientific statements. The study therefore does not mean 10,000 trials proved cannabis cures cancer.
Where is the evidence strongest?
The clearest practical role has been symptom relief rather than tumour treatment, particularly chemotherapy-related nausea and vomiting.
Some countries use medicines such as dronabinol and nabilone for this purpose, especially when conventional antiemetics have not worked sufficiently. This differs fundamentally from claiming cannabis treats the tumour.
Cannabis and chemotherapy-related nausea
Chemotherapy-induced nausea and vomiting are among the best-studied oncology applications. Some controlled trials support particular cannabinoid medicines for patients whose symptoms remain inadequately controlled.
Modern antiemetic regimens have also improved substantially. Cannabinoids are therefore an option for selected cases rather than an automatic first choice.
A standardised cannabinoid medicine must also be distinguished from an extract of unknown composition.
Cannabis and cancer pain
Cannabinoids have also been studied for cancer-related pain.
Some trials of standardised THC/CBD preparations have reported additional relief for certain patients whose pain was inadequately controlled with other medicines.
Results are not consistent enough to justify replacing conventional cancer-pain treatment. Management depends on:
- the cause of pain;
- tumour type and location;
- nerve damage;
- inflammation;
- cancer medicines being used;
- other medicines.
A single universal cannabis dose for cancer pain is therefore not medically justified.
Cannabis and appetite
THC can increase appetite.
This has prompted research into reduced appetite associated with serious illness and cancer.
However, cancer cachexia involves severe weight and muscle loss and is complex to treat. Increasing appetite alone may not resolve it. Other medicines have outperformed cannabinoids in some studies.
Cannabis is therefore not a universal treatment for cancer-related weight loss.
Sleep and anxiety in people with cancer
Many patients report better sleep, less anxiety or improved well-being with cannabis, including in observational studies. Such studies cannot always separate:
- the drug’s pharmacological effects;
- placebo effects;
- changes in the disease;
- effects of concurrent cancer treatment;
- effects of other medicines.
Patient experiences matter, but do not replace controlled trials.
Can CBD cure cancer?
CBD is also the subject of many cancer claims.
Our cannabinoid guide explains how CBD differs from CBG and CBN.
Laboratory studies have examined CBD in different cancer-cell lines and identified effects on some tumour-related processes. Clinical evidence does not establish ordinary CBD oil as a human cancer treatment.
Replacing cancer therapy with CBD is particularly concerning if it delays proven care. CBD can also affect how medicines are metabolised.
Can THC cure cancer?
The distinction is similar for THC. Potential antitumour effects have been studied in cells and animals, but high-THC cannabis or oil is not thereby an established cancer medicine. THC also has psychoactive side effects that vary with amount and individual sensitivity.
What about Rick Simpson Oil?
RSO is a concentrated cannabis extract frequently promoted online as a cancer cure. Our Rick Simpson Oil guide examines these claims and Estonian law. Much of its popularity rests on Rick Simpson’s personal claims and online accounts. High-quality clinical trials have not established that RSO cures cancer.
A high-THC extract can cause strong adverse effects and may have an uncertain composition. It must not be treated as a substitute for established cancer care.
Can cannabis interfere with cancer treatment?
This is often overlooked online. THC, CBD and other cannabinoids can affect liver enzymes involved in breaking down many medicines, creating interaction risks. A patient may simultaneously receive:
- chemotherapy;
- immunotherapy;
- pain medicines;
- anticoagulants;
- antidepressants;
- anti-nausea medicines;
- sleeping medicines.
Changed medicine concentrations can matter clinically. Always tell the oncologist or treating clinician about cannabinoid use.
Cannabis and immunotherapy
Some observational studies have associated cannabis use with poorer immunotherapy outcomes; other findings have been less clear.
High-quality evidence is insufficient for a universal conclusion. This uncertainty makes it especially important to discuss cannabinoid products with the treating team before using them during immunotherapy.
Can cannabis replace opioids?
Online claims sometimes suggest cancer patients can completely stop opioids using cannabis. Adding cannabinoids may help some patients or alter medication needs, but this is not a general rule. Opioids remain important for severe cancer pain; abruptly stopping prescribed treatment without supervision can be dangerous.
Changes should be agreed with the clinician.
What adverse effects are possible?
THC-containing products can cause:
- dizziness;
- sleepiness;
- impaired attention;
- coordination problems;
- anxiety;
- panic;
- increased heart rate;
- confusion;
- memory problems.
Older, frail or heavily medicated patients may be more susceptible.
CBD does not cause THC’s characteristic intoxication, but it also has adverse effects.
These can include:
- fatigue;
- digestive problems;
- drug interactions;
- changes in liver enzymes.
Medical cannabis in Estonia
Medical use does not mean a cancer patient may freely buy or grow high-THC cannabis.
The State Agency of Medicines describes medical use as standardised cannabinoid medicines or standardised cannabis material specifically produced for medical purposes.
Where clinically justified, access can be sought through the regulated medicines system, including an application for an unauthorised medicine. A doctor assesses the need. Cultivation to produce a narcotic substance is prohibited. Our Estonian cannabis legality guide provides further context.
Why is it not routine cancer treatment in Estonia?
One reason is evidence quality. For particular symptoms, clinicians often have medicines with:
- better-established effectiveness;
- standardised doses;
- better-understood interactions;
- more adverse-effect data.
A cannabinoid medicine may be a reasonable additional option in selected circumstances, especially after conventional treatment fails. That is different from presenting it as a universal cancer therapy.
What should a patient do if interested?
Speak with the oncologist or treating clinician and specify:
- the proposed product;
- whether it contains THC, CBD or both;
- other medicines being taken;
- the symptom you hope to relieve.
This allows assessment of interactions and better-studied or standardised alternatives. Do not hide product use out of concern that the doctor will automatically disapprove.
The care team needs to know about every substance and supplement used.
Is cancer research continuing?
Yes. The cannabinoid system remains biologically interesting, with research into:
- cannabinoid receptors;
- tumour-cell signalling;
- combinations with other medicines;
- symptom relief;
- potential interactions.
A cannabinoid or medicine acting on this system may eventually prove useful for a particular tumour. Current evidence does not justify the general claim that cannabis cures cancer.
FAQ
Does cannabis cure cancer?
Clinical evidence is insufficient to establish cannabis as a human cancer treatment. Laboratory findings are interesting but are not equivalent to proven clinical benefit.
Can cannabinoids help during chemotherapy?
Certain cannabinoid medicines have evidence for chemotherapy-related nausea and vomiting, especially when usual treatment is inadequate. They are not appropriate for every patient.
Can cannabis relieve cancer pain?
Some trials have reported relief in some patients, but evidence does not justify replacing conventional cancer-pain care with cannabis.
Does CBD oil cure cancer?
There is currently no reliable clinical evidence establishing ordinary CBD oil as a cancer cure.
Does RSO cure cancer?
High-quality clinical evidence does not establish RSO as a cancer cure.
Can a cancer patient access medical cannabis in Estonia?
Some standardised cannabinoid medicines or medical cannabis preparations may be accessible through Estonia’s regulated medicines system following a clinician’s application.
This does not legalise ordinary recreational cannabis.
Conclusion
Both extremes should be avoided. It is inaccurate to dismiss every potential oncology use of cannabinoids.
Certain medicines have evidence for chemotherapy-related nausea and vomiting, while pain, appetite and other symptoms have also been studied. Cannabis, CBD oil and RSO have not been established as cures for human cancer.
Laboratory antitumour activity is different from clinically proven cancer treatment.
The large 2025 literature analysis found many supportive statements about potential benefits. Automated sentiment classification does not turn all those papers into successful clinical cancer trials.
The clearest current role is symptom relief in selected patients under medical supervision. Decisions about treating the cancer itself should continue to rely on controlled clinical evidence and established oncology care.
Sources
- CDC: cannabis and cancer
- National Cancer Institute: cannabis and cannabinoids
- Castle et al. (2025): literature analysis, Frontiers in Oncology
Estonian State Agency of Medicines: medical cannabis and access
